Research Papers:
Increased expression of ZEB1-AS1 correlates with higher histopathological grade and promotes tumorigenesis in bladder cancer
Metrics: PDF 1684 views | HTML 2235 views | ?
Abstract
Junhao Lin1,3,*, Yonghao Zhan1,2,*, Yuchen Liu1,*, Zhicong Chen1, Jianbo Liang3, Wei Li3, Anbang He1, Liqun Zhou2, Hongbin Mei1, Feng Wang1, Weiren Huang1,2
1Department of Urology, State Engineering Laboratory of Medical Key Technologies Application of Synthetic Biology, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, Guangdong, China
2Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, 100034, Beijing, China
3Department of Urology, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, China
*These authors have contributed equally to this work
Correspondence to:
Weiren Huang, email: [email protected]
Keywords: long non-coding RNA, ZEB1-AS1, tumorigenesis, histopathological grade, bladder cancer
Received: June 15, 2016 Accepted: January 04, 2017 Published: February 20, 2017
ABSTRACT
Bladder cancer is one of the most common urinary cancers worldwide. Emerging studies indicated that long non-coding RNAs (lncRNAs) play crucial roles in cancer biology. In this study, we found that a novel lncRNA Zinc finger E-box-binding homeebox1 (ZEB1) antisense RNA (ZEB1-AS1) was overexpressed in bladder cancer tissues compared to paired noncancerous tissues. Moreover, the expression of ZEB1-AS1 was positive correlated with higher histological grade and TNM stage in bladder cancer. Furthermore, Loss-of-function experiments showed that down-regulation of ZEB1-AS1 not only can suppress cell growth but also can inhibit migration and induce apoptosis in bladder cancer cell lines 5637 and SW780. In conclusion, these findings indicated that ZEB1-AS1 plays regulatory roles in bladder cancer and it may become a novel molecular biomarker of prognosis and therapy in bladder cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15527